Dr. Baas on Next Steps in the Treatment of Mesothelioma

Paul Baas, MD
Published: Thursday, Aug 18, 2016



Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

He maintains that chemotherapy will continue to be extremely relevant in mesothelioma given its efficacy and moderate toxicity. He also highlights that immunotherapy will continue to play a role in this field.

In terms of the differentiation of subtypes of mesothelioma, Baas discusses the identification of groups of patients that may benefit from arginine deprivation treatment, especially in the sarcomatoid type.


Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

He maintains that chemotherapy will continue to be extremely relevant in mesothelioma given its efficacy and moderate toxicity. He also highlights that immunotherapy will continue to play a role in this field.

In terms of the differentiation of subtypes of mesothelioma, Baas discusses the identification of groups of patients that may benefit from arginine deprivation treatment, especially in the sarcomatoid type.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x